2755644-33-6
2755644-33-6
Chemical Structure
Epalrestat-d5
Synonym(s): ONO2235-d5
- CAS No.: 2755644-33-6
- Formula:C15H8D5NO3S2
- Molecular Weight:324.43
IUPAC Name: 2-((Z)-5-((E)-2-methyl-3-(phenyl-d5)allylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid
InChIKey: CHNUOJQWGUIOLD-CUEOMABLSA-N
SMILES: O=C(N1CC(O)=O)/C(SC1=S)=C/C(C)=C/C2=C(C([2H])=C(C([2H])=C2[2H])[2H])[2H]
Biological Activity: Epalrestat-d5 is deuterium labeled Epalrestat. Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Epalrestat-d5 | Epalrestat-d5 is deuterium labeled Epalrestat. Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Epalrestat (Standard) | 98.59% | Epalrestat (Standard) is the analytical standard of Epalrestat. This product is intended for research and analytical applications. Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Epalrestat | 99.62% | Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. Ramirez, M.A. and N.L. Borja, Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy. Pharmacotherapy, 2008. 28(5): p. 646-55. [Content Brief]
- [3]. He J, et al. The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation. Acta Pharmacol Sin. 2019 Jan;40(1):86-97. [Content Brief]
- [4]. Okamoto, H., et al., Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis. Intern Med, 2003. 42(8): p. 655-64. [Content Brief]
